Stocktoria
PALVELLA THERAPEUTICS, INC. PVLA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-12-18
Chart by TradingView
1/9
Piotroski F — financial health
-5.59
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | $38.7M | $25.9M | $27.9M |
| Operating income | -$38.6M | -$14.1M | -$11.9M | -$43.5M | -$51.8M |
| Net income | -$41.7M | -$17.4M | $18.7M | -$33.3M | -$45.7M |
| Operating cash flow | -$25.0M | -$10.8M | -$13.7M | -$59.9M | -$7.7M |
| Free cash flow | — | — | -$13.9M | -$61.0M | -$8.6M |
| Total assets | $59.6M | $88.2M | $7.5M | $95.5M | $153.6M |
| Total liabilities | $31.6M | $25.6M | $11.4M | $67.6M | $102.8M |
| Shareholders' equity | $28.0M | $62.6M | -$74.5M | -$93.8M | $50.8M |
| Ratios | |||||
| Operating margin | — | — | -30.7% | -167.8% | -185.5% |
| Net margin | — | — | 48.3% | -128.5% | -163.7% |
| FCF margin | — | — | -35.8% | -235.4% | -30.8% |
| Return on assets | -70.0% | -19.8% | 247.6% | -34.8% | -29.8% |
| Return on equity | -149.1% | -27.8% | -25.1% | 35.5% | -90.1% |
| Current ratio | 5.20 | 7.33 | 3.20 | 2.01 | 2.52 |
| Revenue growth | — | — | 49.5% | -7.3% | 16.8% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 88,160 | $11.0M |
| RENAISSANCE TECHNOLOGIES LLC | 17,970 | $2.2M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -5.59 (distress)
- Working capital / assets 0.8
- Retained earnings / assets -2.274
- EBIT / assets -0.648
- Equity / liabilities 0.886
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001583648 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.